Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

pembrolizumab 2Etoposide 2Cyclophosphamide 2talimogene laherparepvec 1romidepsin 1prednylidene 1fludarabine phosphate 1etoposide phosphate 1entrectinib 1deltacortene 1Whole-Body Irradiation 1Valganciclovir 1Therapeutics 1Tacrolimus 1Specimen Handling 1Sirolimus 1Prednisone 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Maintenance 1Lactones 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Doxorubicin 1Depsipeptides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Large-Cell, Anaplastic × Lactones × Clear all
NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡